publication date: May. 12, 2017

In Brief

Robert Vonderheide new UPenn Abramson Cancer Center director

Robert Vonderheide, an expert in cancer immunotherapy and translational research, was named director of the Abramson Cancer Center of the University of Pennsylvania.

He is the Hanna Wise Professor in Cancer Research at the Perelman School of Medicine, and currently serves as the Abramson Cancer Center’s associate director for translational research and executive director of its Translational Centers of Excellence Program. He will begin his new role on July 1.

“Dr. Vonderheide’s career at Penn has been marked by continuous innovation in areas that were scarcely a possibility in the field when he arrived here in 2001,” said J. Larry Jameson, dean of the Perelman School of Medicine and executive vice president of the University of Pennsylvania for the Health System. “At each step, he has executed visionary ideas that have propelled translational research advances and made immunotherapy a crucial prong of the fight against cancer. He is uniquely qualified to lead the search for the next generation of treatments and cures.”

Vonderheide succeeds Chi Van Dang, who has served as the ACC’s director since 2011 and who will become scientific director of the Ludwig Institute.

The Abramson Cancer Center provides care during more than 230,000 outpatient visits annually, as well as delivering more than 37,000 chemotherapy treatments, over 66,000 radiation treatments and 230 stem cell transplants each year.

In 2015, the ACC was rated as “exceptional” during a competitive research funding review, the highest possible rating for an NCI Cancer Center.

The ACC is also home to more than 400 basic, translational and clinical scientists who work in tandem to advance new … Continue reading Robert Vonderheide new UPenn Abramson Cancer Center director

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.